BlackRock’s Kyntra Bio KYNB Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q2 | $637K | Sell |
84,330
-1
| -0% | -$7 | ﹤0.01% | 4499 |
|
|
2026
Q1 | $572K | Sell |
84,331
-359
| -0.4% | -$2.81K | ﹤0.01% | 4491 |
|
|
2025
Q4 | $744K | Sell |
84,690
-61
| -0.1% | -$596 | ﹤0.01% | 4388 |
|
|
2025
Q3 | $1.04M | Hold |
84,751
| – | – | ﹤0.01% | 4275 |
|
|
2025
Q2 | $449K | Sell |
84,751
-10,143
| -11% | -$74K | ﹤0.01% | 4472 |
|
|
2025
Q1 | $735K | Sell |
94,894
-187
| -0.2% | -$2.24K | ﹤0.01% | 4282 |
|
|
2024
Q4 | $1.26M | Sell |
95,081
-577
| -0.6% | -$5.36K | ﹤0.01% | 4175 |
|
|
2024
Q3 | $955K | Sell |
95,658
-728
| -0.8% | -$11K | ﹤0.01% | 4182 |
|
|
2024
Q2 | $2.15M | Sell |
96,386
-182,331
| -65% | -$5.63M | ﹤0.01% | 3948 |
|
|
2024
Q1 | $16.4M | Sell |
278,717
-9,495
| -3% | -$409K | ﹤0.01% | 3099 |
|
|
2023
Q4 | $6.39M | Sell |
288,212
-33,216
| -10% | -$501K | ﹤0.01% | 3591 |
|
|
2023
Q3 | $6.93M | Sell |
321,428
-37,836
| -11% | -$1.49M | ﹤0.01% | 3522 |
|
|
2023
Q2 | $24.3M | Buy |
359,264
+66,719
| +23% | +$27.6M | ﹤0.01% | 2913 |
|
|
2023
Q1 | $136M | Buy |
292,545
+7,172
| +3% | +$3.79M | ﹤0.01% | 1824 |
|
|
2022
Q4 | $114M | Sell |
285,373
-1,300
| -0.5% | -$498K | ﹤0.01% | 1907 |
|
|
2022
Q3 | $93.2M | Buy |
286,673
+10,139
| +4% | +$3.27M | ﹤0.01% | 2015 |
|
|
2022
Q2 | $73M | Buy |
276,534
+10,082
| +4% | +$2.58M | ﹤0.01% | 2235 |
|
|
2022
Q1 | $80.1M | Buy |
266,452
+630
| +0.2% | +$220K | ﹤0.01% | 2276 |
|
|
2021
Q4 | $93.7M | Buy |
265,822
+391
| +0.1% | +$122K | ﹤0.01% | 2254 |
|
|
2021
Q3 | $67.8M | Sell |
265,431
-24,226
| -8% | -$8.58M | ﹤0.01% | 2460 |
|
|
2021
Q2 | $193M | Sell |
289,657
-15,385
| -5% | -$8.86M | 0.01% | 1789 |
|
|
2021
Q1 | $265M | Sell |
305,042
-10,862
| -3% | -$11.6M | 0.01% | 1512 |
|
|
2020
Q4 | $293M | Buy |
315,904
+14,582
| +5% | +$15.3M | 0.01% | 1322 |
|
|
2020
Q3 | $310M | Sell |
301,322
-16,607
| -5% | -$17.9M | 0.01% | 1049 |
|
|
2020
Q2 | $322M | Buy |
317,929
+37,304
| +13% | +$34.6M | 0.01% | 1001 |
|
|
2020
Q1 | $244M | Buy |
280,625
+15,545
| +6% | +$15.5M | 0.01% | 1020 |
|
|
2019
Q4 | $284M | Buy |
265,080
+1,990
| +0.8% | +$2.03M | 0.01% | 1215 |
|
|
2019
Q3 | $243M | Buy |
263,090
+13,765
| +6% | +$15.1M | 0.01% | 1263 |
|
|
2019
Q2 | $282M | Buy |
249,325
+2,410
| +1% | +$2.64M | 0.01% | 1170 |
|
|
2019
Q1 | $335M | Sell |
246,915
-5,455
| -2% | -$7.4M | 0.02% | 1031 |
|
|
2018
Q4 | $292M | Buy |
252,370
+325
| +0.1% | +$365K | 0.01% | 1024 |
|
|
2018
Q3 | $383M | Buy |
252,045
+4,739
| +2% | +$7.3M | 0.02% | 962 |
|
|
2018
Q2 | $387M | Buy |
247,306
+10,879
| +5% | +$14.2M | 0.02% | 933 |
|
|
2018
Q1 | $273M | Sell |
236,427
-16,616
| -7% | -$21.9M | 0.01% | 1118 |
|
|
2017
Q4 | $300M | Buy |
253,043
+9,785
| +4% | +$12.3M | 0.01% | 1075 |
|
|
2017
Q3 | $327M | Buy |
243,258
+43,202
| +22% | +$45.5M | 0.02% | 960 |
|
|
2017
Q2 | $162M | Buy |
200,056
+21,863
| +12% | +$15.2M | 0.01% | 1454 |
|
|
2017
Q1 | $110M | Buy |
178,193
+177,596
| +29,748% | +$108M | 0.01% | 1727 |
|
|
2016
Q4 | $319K | Sell |
597
-203
| -25% | -$101K | ﹤0.01% | 1885 |
|
|
2016
Q3 | $413K | Buy |
800
+284
| +55% | +$134K | ﹤0.01% | 1813 |
|
|
2016
Q2 | $212K | Buy |
516
+383
| +288% | +$175K | ﹤0.01% | 2068 |
|
|
2016
Q1 | $70K | Buy |
133
+72
| +118% | +$35.9K | ﹤0.01% | 2178 |
|
|
2015
Q4 | $46K | Buy |
61
+7
| +13% | +$4.64K | ﹤0.01% | 2100 |
|
|
2015
Q3 | $30K | Buy |
54
+11
| +26% | +$6.66K | ﹤0.01% | 2151 |
|
|
2015
Q2 | $25K | Buy |
43
+34
| +378% | +$19.8K | ﹤0.01% | 2290 |
|
|
2015
Q1 | $7K | Hold |
9
| – | – | ﹤0.01% | 2908 |
|
|
2014
Q4 | $6K | Buy |
+9
| New | +$5.79K | ﹤0.01% | 3000 |
|
Other funds holding KYNB
AC
BC
BlackRock's KYNB Position: Q2 2026 in Review
BlackRock reduced its Kyntra Bio (KYNB) stake by 0% in Q2 2026, selling an estimated $7 and leaving 84,330 shares worth $637K. The position accounts for ﹤0.01% of the portfolio, ranked #4499.
BlackRock first reported a position in KYNB in Q4 2014 and has held it in 47 quarters since. The position peaked at $387M in Q2 2018. 27 funds tracked by Wall St. Rank hold KYNB as of Q2 2026.
- BlackRock held 84,330 shares of Kyntra Bio worth $637K as of Q2 2026.
- BlackRock sold 1 Kyntra Bio share in Q2 2026, an estimated $7.
- Kyntra Bio made up ﹤0.01% of BlackRock's portfolio in Q2 2026, its #4499 holding.
- BlackRock first reported a position in Kyntra Bio in Q4 2014 and has held it in 47 quarters since.
- BlackRock's Kyntra Bio position peaked at $387M in Q2 2018.
- 27 funds tracked by Wall St. Rank held Kyntra Bio as of Q2 2026.
Based on BlackRock's 13F filing for Q2 2026, filed 7 Aug 2026.